Skip to main content
. Author manuscript; available in PMC: 2022 Sep 21.
Published in final edited form as: Nat Biotechnol. 2022 Mar 3;40(8):1270–1275. doi: 10.1038/s41587-022-01232-2

Figure 3. Assessment of LIBRA-seq with ligand blocking.

Figure 3.

A. “Predicted Neutralizing Antibodies” were defined as the subset of selected antibodies with negative ACE2 LIBRA-seq scores from experiments 1 (n=7 antibodies) and 3 (n=6 antibodies), and all antibodies with high LIBRA-seq scores (>1) for SARS-CoV-2 S from experiment 2 (n=7 antibodies). The percent of neutralizing antibodies from the set of predicted neutralizers is shown for each experiment. B. The IC50 values (μg/mL) for SARS-CoV-2 neutralization by RTCA with VSV-SARS-CoV-2 (IC50 value for each antibody shown as single dot) are plotted for the set of predicted neutralizers. Horizontal line shown is geometric mean for each experiment. Non-neutralizing antibodies are shown as >10 μg/mL. C. Spearman correlation of ACE2 LIBRA-seq score (x-axis) and % Reduction in ACE2 Binding to SARS-CoV-2 (y-axis) for antibodies from experiments 1 and 3. Spearman r = −0.54, p = 0.017 (two-tailed, 95% confidence interval).